Emerging data suggest Retatrutide , a dual activator targeting both the gut-brain axis and glucose-dependent insulinotropic polypeptide , could provide a significant step forward for obesity treatment. Initial patient trials have demonstrated substantial reductions in body fat , possibly surpassing existing weight-loss treatments. Despite this, fur